Guardion Health Sciences (Guardion Health Sciences) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Guardion Health Sciences Debt-to-Equity?

Guardion Health Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Guardion Health Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Guardion Health Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $3.41 Mil. Guardion Health Sciences's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Guardion Health Sciences's Debt-to-Equity or its related term are showing as below:

During the past 9 years, the highest Debt-to-Equity Ratio of Guardion Health Sciences was 0.40. The lowest was -1.10. And the median was 0.01.

GHSI's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Guardion Health Sciences Debt-to-Equity Historical Data

The historical data trend for Guardion Health Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardion Health Sciences Debt-to-Equity Chart

Guardion Health Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.05

Guardion Health Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Guardion Health Sciences's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Guardion Health Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guardion Health Sciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guardion Health Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Guardion Health Sciences's Debt-to-Equity falls into.

Guardion Health Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Guardion Health Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	8.146
	=	0.00

Guardion Health Sciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.414
	=	0.00

Guardion Health Sciences (NAS:GHSI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Guardion Health Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardion Health Sciences (Guardion Health Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (NAS:GHSI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0QTA:Germany

Address

2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098

Website

https://www.guardionhealth.com

Guardion Health Sciences Inc is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product. The company's Medical Foods include Lumega-Z and GlaucoCetin; Medical Devices include Mapcat SF, VectorVision, CSV-1000 and CSV-2000; Nutraceuticals include ImmuneSF.

Executives

Katharine Joan Cox	officer: Chief Accounting Officer	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Janet Hall	officer: CEO & President	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bradley Louis Radoff	10 percent owner	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Family Foundation Radoff	other: See Footnote 1	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Michaela Griggs	director	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bret Scholtes	director, officer: Chief Executive Officer	2105 CITY WEST BLVD., SUITE 500, HOUSTON TX 77042
Donald A Gagliano	director	131 CARDINAL AVE, SAN ANTONIO TX 78209
Jeffrey S Benjamin	officer: Chief Accounting Officer	3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
Craig Sheehan	officer: Chief Commercial Officer	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andrew C Schmidt	officer: Chief Financial Officer	1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Kelly Anderson	director	C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
David W Evans	director, officer: Chief Scientific Officer	4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Tamara A Evans	10 percent owner	4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Vincent J Roth	officer: General Counsel and Secretary	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Robert N Weingarten	director	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367